<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462005</url>
  </required_header>
  <id_info>
    <org_study_id>Ranger SFA Registry</org_study_id>
    <nct_id>NCT02462005</nct_id>
  </id_info>
  <brief_title>Treatment of Femoro-popliteal Atherosclerotic Lesions Using the Ranger Paclitaxel Coated Balloon Catheter. All Comers Registry.</brief_title>
  <official_title>Ranger DEB All Comers Registry - Treatment of Femoro-popliteal Atherosclerotic Lesions Using the Ranger Paclitaxel Coated Balloon Catheter: An All Comers Registry.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum Arnsberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Klinikum Arnsberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of up to 250 patients from an all-comers patient population with infrainguinal
      atherosclerotic disease who are implanted or scheduled for an implant with a Ranger Drug
      coated balloon.

      Interim analysis will be carried out for every 50 subjects enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Clinical primary endpoint: Major Adverse Events (MAE) defined as composite of freedom from device- and procedure-related mortality through 30 days, freedom from major target limb amputation and TLR within 6 months post-index procedure.</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance primary endpoint: Primary patency at 12 months, defined as freedom from &gt; 50% restenosis with no clinically-driven reintervention</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary patency at 6 and 24 months, defined as freedom from &gt; 50% restenosis with no clinically-driven reintervention</measure>
    <time_frame>6 and 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAE at 12 and 24 months</measure>
    <time_frame>12 and 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success, defined as successful vascular access and completion of the endovascular procedure and immediate morphological success with ≤ 50% residual stenosis (visual assessment)</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success, defined as exact deployment of the device according to the IFU (operator assessment)</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success, defined as the combination of technical success and device success</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle-Brachial Index (ABI) at 6, 12 and 24 months (and prior to any reintervention)</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of at least one Rutherford class at 6, 12 and 24 months (an prior to any reintervention) compared to the pre-procedure Rutherford classification.</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR) and Target Vessel Revascularization (TVR) at 6, 12 and 24 months.</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limb salvage, defined as preservation of the treated limb with no need for any amputation at 6, 12 and 24 months.</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of pain score at 6, 12 and 24 months compared to the pre-procedure score</measure>
    <time_frame>6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Atherosclerotic Disease</condition>
  <arm_group>
    <arm_group_label>ALL COMERS</arm_group_label>
    <description>Patients implanted or scheduled for an implant with a Ranger Drug coated balloon.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from an all-comers patient population with infrainguinal atherosclerotic disease
        who are implanted or scheduled for an implant with a Ranger Drug coated balloon and who
        fulfill the in/exclusion criteria at approved investigational centres are eligible for
        participation in the Ranger DEB-Comers Registry.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years.

          -  Patient must be willing to sign a a patient informed consent form.

          -  Patient with de novo, restenotic or reoccluded lesions in the infrainguinal .arteries
             implanted or scheduled for an implant with a Ranger Drug coated balloon.

          -  Target vessel reference diameter 2.5 to 8 mm.

        Exclusion Criteria:

          -  Subjects pregnant or planning to become pregnant during the course of the study.

          -  Life expectancy of less than 1 year.

          -  Known allergy to concomitant medication, contrast agents (that cannot be medically
             managed), anti-platelet, anti-coagulant or thrombolytic medications. Subject enrolled
             in another study that has not reached its primary endpoint at the time of enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Lichtenberg, Dr.med. Dr.oec.med.</last_name>
    <phone>+49 (0)2932 952</phone>
    <phone_ext>1271</phone_ext>
    <email>m.lichtenberg@klinikum-arnsberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum Arnsberg</name>
      <address>
        <city>Arnsberg</city>
        <zip>59759</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lichtenberg, Dr. med. Dr. oec. med.</last_name>
      <phone>+49 (0)2932 952</phone>
      <phone_ext>1271</phone_ext>
      <email>M.Lichtenberg@klinikum-arnsberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Martin Kuhmann, Dr. oec.troph.</last_name>
      <phone>+49 (0)251 2896515</phone>
      <email>clinical@kuhmann-ms.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus Bottrop</name>
      <address>
        <city>Bottrop</city>
        <zip>46242</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Ranft, Dr. med.</last_name>
      <phone>+49 (0)2041 15 11</phone>
      <phone_ext>00 / 01</phone_ext>
      <email>juergen.ranft@kk-bottrop.de</email>
    </contact>
    <contact_backup>
      <last_name>Kathrin Niemöller, Dr. med.</last_name>
      <phone>+49 (0)2041 15 11</phone>
      <phone_ext>00 / 01</phone_ext>
      <email>kathrin.niemoeller@kk-bottrop.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>SRH Klinikum Karlsbad-Langensteinbach GmbH</name>
      <address>
        <city>Karlsbad-Langensteinbach</city>
        <zip>76307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwin Blessing, Prof. Dr. med.</last_name>
      <phone>+49 (0)7202 61</phone>
      <phone_ext>3340</phone_ext>
      <email>erwin.blessing@kkl.srh.de</email>
    </contact>
    <contact_backup>
      <last_name>Bernd Kroeg</last_name>
      <phone>+49 (0)7202 61</phone>
      <phone_ext>3471</phone_ext>
      <email>Bernd.Kroeg@kkl.srh.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Gefaesspraxis im Tal</name>
      <address>
        <city>Muenchen</city>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Baron von Bilderling, Dr. med.</last_name>
      <phone>+49 (0)89 24 21</phone>
      <phone_ext>58 82</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Christine Bludau</last_name>
      <phone>+49 (0)89 24 21</phone>
      <phone_ext>586</phone_ext>
      <email>Christine.bludau@angiopraxis.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder Trier</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Grell, Dr. med.</last_name>
      <phone>+49 (0)651 208</phone>
      <phone_ext>1856</phone_ext>
      <email>H.Grell@bk-trier.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUV, Service de Chirurgie Vasculaire</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Saucy, Dr.</last_name>
      <phone>+41 (0)21 314 28 05</phone>
      <email>francois.saucy@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Lukas Briner, Dr.</last_name>
      <phone>+41 (0)21 314 05 76</phone>
      <email>Lukas.Briner@chuv.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

